Rhumbline Advisers Increases Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Rhumbline Advisers increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,958 shares of the company’s stock after buying an additional 1,631 shares during the quarter. Rhumbline Advisers owned 0.19% of Amphastar Pharmaceuticals worth $2,579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its stake in Amphastar Pharmaceuticals by 4,151.3% during the 1st quarter. GAMMA Investing LLC now owns 38,644 shares of the company’s stock worth $1,120,000 after buying an additional 37,735 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Amphastar Pharmaceuticals during the 4th quarter worth $38,000. Voloridge Investment Management LLC grew its stake in Amphastar Pharmaceuticals by 16.2% during the 4th quarter. Voloridge Investment Management LLC now owns 143,436 shares of the company’s stock worth $5,326,000 after buying an additional 19,991 shares during the last quarter. Squarepoint Ops LLC grew its stake in Amphastar Pharmaceuticals by 208.0% during the 4th quarter. Squarepoint Ops LLC now owns 17,664 shares of the company’s stock worth $656,000 after buying an additional 11,929 shares during the last quarter. Finally, Twinbeech Capital LP purchased a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at about $1,738,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 2.3%

Shares of AMPH opened at $25.82 on Monday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of 8.61, a PEG ratio of 2.19 and a beta of 0.77. The stock’s 50-day moving average price is $24.67 and its 200-day moving average price is $30.77.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.